IAccumulated safety data of micafungin in therapy and prophylaxis in fungal diseases

Expert Opinion on Drug Safety

Volumn 10, Issue 2, 2011, Pages 171-183

  Cornely, Oliver A ^a,b   Pappas, Peter G ^c   Young, Jo Anne H ^d   Maddison, Philip ^e   Ullmann, Andrew J ^f  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e Astellas Pharma Global Development   (Netherlands)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

antifungal; candidemia; candidiasis; micafungin

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; MICAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; LIPOPEPTIDE;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INCUBATION TIME; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NAUSEA; NEUTROPENIA; PHLEBITIS; PRESCHOOL CHILD; PROPHYLAXIS; RASH; RIGOR; SCHOOL CHILD; SIDE EFFECT; UREA BLOOD LEVEL; VOMITING; AGE; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; FACTUAL DATABASE; INFANT; MIDDLE AGED; TIME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHINOCANDINS; FEMALE; HUMANS; INFANT; LIPOPEPTIDES; MALE; MIDDLE AGED; MYCOSES; TIME FACTORS; YOUNG ADULT;

EID: 79952383262     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.557062     Document Type: Article

References (43)

1. Warnock DW. Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi 2007;10:1-12 (Pubitemid 46280129)
2. De Pauw BE. Increasing fungal infections in the intensive care unit. Surg Infect (Larchmt) 2006;7(Suppl 2):S93-6
3. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001;33:1692-6 (Pubitemid 33044535)
4. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006;20:485-506 (Pubitemid 44375119)
5. Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care 2002;17:168-75
6. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-9 (Pubitemid 41532664)
7. Fridkin SK. Candidemia is costly-plain and simple. Clin Infect Dis 2005;41:1240-1
8. Zaoutis TE, Heydon K, Chu JH, et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006;117:e711-16
9. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:1172-7 (Pubitemid 37372504)
10. Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004;23:317-22 (Pubitemid 38669942)
11. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005;26:540-7 (Pubitemid 40896144)
12. Horn DL, Fishman JA, Steinbach WJ, et al. Presentation of the PATH Alliance® registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007;59:407-14 (Pubitemid 350186332)
13. Charlier C, Hart E, Lefort A, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006;57:384-410
14. Trick WE, Fridkin SK, Edwards JR, et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-30
15. Sobel JD. The emergence of non-albicans Candida species as causes of invasive candidiasis and candidemia. Curr Infect Dis Rep 2006;8:427-33 (Pubitemid 44717978)
16. Ullmann AJ, Sanz MA, Tramarin A, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006;43:e29-38
17. Gubbins PO, Penzak SR, Polston S, et al. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002;22:961-71 (Pubitemid 34831291)
18. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001;32:686-93 (Pubitemid 32221925)
19. Gibbs WJ, Drew RH, Perfect JR. Liposomal amphotericin B: clinical experience and perspectives. Expert Rev Anti Infect Ther 2005;3:167-81 (Pubitemid 40590323)
20. Cornely OA, Sidhu M, Odeyemi I, et al. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 2008;24:1743-53 (Pubitemid 351929071)
21. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-27 (Pubitemid 46670281)
22. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93 (Pubitemid 47580382)
23. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive Candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008;27:820-6
24. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16 (Pubitemid 39518200)
25. de Wet NT, Bester AJ, Viljoen JJ, et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther 2005;21:899-907 (Pubitemid 40477250)
26. Mycamine: Summary of product characteristics. Astellas Pharma GmbH. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/mycamine/emea- combined-h734en.pdf [Last accessed 8 July 2010]
27. Mycamine® (micafungin sodium) for injection: Prescribing Information. Astellas Pharma US, Inc., January 2008. Available from: http://www.accessdata. fda.gov/drugsatfda-docs/label/2008/021506s008lbl.pdf [Last accessed 8 July 2010]
28. Denning DW. Echinocandin antifungal drugs. Lancet 2003;362:1142-51 (Pubitemid 37222342)
29. Tamura K, Urabe A, Yoshida M, et al. Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders. Leuk Lymphoma 2009;50:92-100
30. EraxisTM (anidulafungin) for injection: Prescribing Information. Pfizer Inc, June 2009. Available from: http://media.pfizer.com/files/products/uspi- eraxis.pdf [Last accessed 8 July 2010]
31. Cancidas® (caspofungin acetate): Prescribing Information. Merck & Co., Inc., February 2010. Available from: http://www.merck.com/product/usa/pi- circulars/c/cancidas/cancidas-pi.pdf [Last accessed 8 July 2010]
32. Vfend® (voriconazole): prescribing Information. Pfizer, Inc, June 2010. Available from: http://www.pfizer.com/files/products/uspi-vfend.pdf [Last accessed 8 July 2010]
33. Diflucan® (fluconazole): Prescribing Information. Pfizer Inc, January 2010. Available from: http://media.pfizer.com/files/products/uspi-diflucan.pdf [Last accessed 8 July 2010]
34. Buell DN, Kovanda L, Drake T, Fisco C. Alternative day dosing of micafungin in the treatment of esophageal candidiasis. Abstract M-719. Presented at the 45th Annual Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC); 16-19 December 2005; Washington DC, USA
35. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005;24:654-61 (Pubitemid 41667052)
36. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004;36:372-9 (Pubitemid 38967695)
37. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39:842-9 (Pubitemid 39244300)
38. Pettengell K, Mynhardt J, Kluyts T, et al. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004;20:475-81 (Pubitemid 39120260)
39. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006;53:337-49 (Pubitemid 44524711)
40. Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005;49:1331-6 (Pubitemid 40463357)
41. Sirohi B, Powles RL, Chopra R, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006;38:47-51 (Pubitemid 43923089)
42. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006;25:1110-15 (Pubitemid 44900673)
43. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005;49:3317-24 (Pubitemid 41060577)